Medicus Pharma Ltd (NASDAQ:MDCX) Sees Large Increase in Short Interest

Medicus Pharma Ltd (NASDAQ:MDCX) was the recipient of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 1,105,825 shares, a growth of 24.4% from the January 15th total of 888,655 shares. Based on an average daily volume of 297,800 shares, the short-interest ratio is presently 3.7 days. Approximately 4.9% of the company’s shares are short sold. Approximately 4.9% of the company’s shares are short sold. Based on an average daily volume of 297,800 shares, the short-interest ratio is presently 3.7 days.

Analysts Set New Price Targets

MDCX has been the topic of a number of research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Medicus Pharma presently has a consensus rating of “Hold” and a consensus target price of $23.50.

Medicus Pharma Trading Up 3.8%

MDCX traded up $0.04 during trading on Tuesday, hitting $1.10. 272,092 shares of the company’s stock were exchanged, compared to its average volume of 394,977. Medicus Pharma has a 1 year low of $0.92 and a 1 year high of $8.94. The stock has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.96. The firm has a market cap of $28.11 million, a P/E ratio of -0.51 and a beta of -1.17.

Medicus Pharma (NASDAQ:MDCX) last posted its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.27). Analysts forecast that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Private Advisor Group LLC grew its stake in shares of Medicus Pharma by 3.8% in the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after buying an additional 5,500 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in Medicus Pharma by 180.0% in the 2nd quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after acquiring an additional 9,000 shares during the period. Jane Street Group LLC acquired a new stake in Medicus Pharma in the second quarter valued at approximately $41,000. Commonwealth Equity Services LLC raised its stake in shares of Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares during the period. Finally, May Hill Capital LLC raised its stake in shares of Medicus Pharma by 100.0% during the fourth quarter. May Hill Capital LLC now owns 35,622 shares of the company’s stock valued at $55,000 after purchasing an additional 17,811 shares during the period.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.